GB934089A - Improvements in or relating to sustained release medicaments - Google Patents

Improvements in or relating to sustained release medicaments

Info

Publication number
GB934089A
GB934089A GB37435/61A GB3743561A GB934089A GB 934089 A GB934089 A GB 934089A GB 37435/61 A GB37435/61 A GB 37435/61A GB 3743561 A GB3743561 A GB 3743561A GB 934089 A GB934089 A GB 934089A
Authority
GB
United Kingdom
Prior art keywords
fatty acid
sustained release
active material
nervous system
central nervous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB37435/61A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceuticals Inc
Original Assignee
McNeilab Inc
McNeil Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by McNeilab Inc, McNeil Laboratories Inc filed Critical McNeilab Inc
Publication of GB934089A publication Critical patent/GB934089A/en
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L39/00—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen; Compositions of derivatives of such polymers
    • C08L39/04—Homopolymers or copolymers of monomers containing heterocyclic rings having nitrogen as ring member
    • C08L39/06—Homopolymers or copolymers of N-vinyl-pyrrolidones

Abstract

A compressed, sustained release oral pharmaceutical preparation, e.g. a tablet, comprises a water-granulated mixture of polyvinyl-pyrrolidone, a hydrophobic fatty acid salt and a therapeutically active material, the composition containing at least about 5% by weight of P.V.P. and the weight ratio of P.V.P. to fatty acid salt being from 1 to about 1 to 1 to about 4. Of the therapeutically active material is water-insoluble, a hydrophilic gum, e.g. carboxymethylcellulose, other methylcelluloses and their sodium salts, gelatin, ueacia and alginates may also be present. The P.V.P. is preferably one having a K value of from about 24 to about 40 and a molecular weight of from about 20,000 to about 100,000. Specified fatty acid salts are those of Al, Ca and Mg. Specified medicaments are chlorzoxazone, antihistamines, e.g. carbinoxamine and rotoxamine, antispasmodics, e.g. poldine, central nervous system depressants, e.g. phenobarbital and butylbarbital, central nervous system stimulants, e.g. methamphetamine, vasodilators, e.g. phenylpropanolamine and phenylephrine, vitamins, e.g. thiamine and pyridoxine and antibiotics, e.g. tetracycline, chlortetracycline, oxytetracycline and penicillins.
GB37435/61A 1960-11-18 1961-10-18 Improvements in or relating to sustained release medicaments Expired GB934089A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US70132A US3102845A (en) 1960-11-18 1960-11-18 Pharmaceutical tablet

Publications (1)

Publication Number Publication Date
GB934089A true GB934089A (en) 1963-08-14

Family

ID=22093330

Family Applications (1)

Application Number Title Priority Date Filing Date
GB37435/61A Expired GB934089A (en) 1960-11-18 1961-10-18 Improvements in or relating to sustained release medicaments

Country Status (3)

Country Link
US (1) US3102845A (en)
DE (1) DE1195012B (en)
GB (1) GB934089A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4609542A (en) * 1978-12-22 1986-09-02 Elan Corporation, P.L.C. New pharmaceutical forms for administration of medicaments by oral route, with programmed release
GB2178658A (en) * 1985-07-26 1987-02-18 Vincent Processes Limited Sustained release tablets and a method of manufacture thereof

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL113366C (en) * 1961-02-24
US3148124A (en) * 1962-06-12 1964-09-08 William E Gaunt Method of preparing sustained release pharmaceutical tablets
DE1467781A1 (en) * 1963-07-15 1968-12-05 Boehringer Sohn Ingelheim Process for the production of coated tablets with extended release of active ingredients
US4091091A (en) * 1973-11-08 1978-05-23 Eli Lilly And Company Stabilized nitroglycerin tablets
DE2551446B2 (en) * 1975-11-15 1977-09-15 Karl Werner Schlüter GmbH, 2000 Ham burg METHOD OF MANUFACTURING SUPPOSITORIES
JPS55153715A (en) * 1979-05-18 1980-11-29 Nikken Kagaku Kk Prolonged granule of theophylline
US4264573A (en) * 1979-05-21 1981-04-28 Rowell Laboratories, Inc. Pharmaceutical formulation for slow release via controlled surface erosion
JPS6056122B2 (en) * 1980-05-21 1985-12-09 塩野義製薬株式会社 sustained release formulation
HU183408B (en) 1981-04-28 1984-05-28 Chinoin Gyogyszer Es Vegyeszet Process for producing oral ratard pharmaceutical compositions
DE3124983A1 (en) * 1981-06-25 1983-01-20 Meditest Inst Fuer Medizinisch ORAL ADMINISTRATIVE FORMS
US4327080A (en) * 1981-07-13 1982-04-27 E. R. Squibb & Sons, Inc. Novel Bendroflumethiazide formulations and method

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2385920A (en) * 1941-12-19 1945-10-02 Pittsburgh Plate Glass Co Plasticization of plastics
US2606195A (en) * 1947-11-19 1952-08-05 Wm S Merrell Co Aryl pyridyl carbinol ethers
US2776924A (en) * 1954-02-05 1957-01-08 Coty Inc Composition of matter containing polyvinylpyrrolidone and a fatty carrier
US2820741A (en) * 1954-04-29 1958-01-21 Abbott Lab Aluminum aspirin granulation and method for making
US2897120A (en) * 1954-05-04 1959-07-28 Upjohn Co Low viscosity cmc pharmaceutical vehicle
US2841528A (en) * 1954-09-21 1958-07-01 Collett & Co As Method of making fused tablets
US2811483A (en) * 1954-12-09 1957-10-29 Pfizer & Co C Pharmaceutical composition and process for preparing the same
US2819981A (en) * 1955-02-23 1958-01-14 Goodrich Co B F Method for making flexible, vapor-permeable, water-resistant vinyl films and the like having improved slip and hand
US2890985A (en) * 1955-08-08 1959-06-16 Sam Joseph Composition and method for relieving spasticity
US2894289A (en) * 1956-03-01 1959-07-14 Dow Chemical Co Method of making permeselective membranes
US2895877A (en) * 1956-07-30 1959-07-21 Mcneilab Inc Composition and method for relieving spasticity
US2887437A (en) * 1956-08-22 1959-05-19 Pfizer & Co C Palatable vitamin tablet containing an amino acid
US2887439A (en) * 1956-09-28 1959-05-19 Pfizer & Co C Palatable antihistamine tablet
US2897121A (en) * 1957-06-04 1959-07-28 Upjohn Co Pharmaceutical composition
US2918411A (en) * 1957-11-01 1959-12-22 Olin Mathieson Pharmaceutical preparations
NL109170C (en) * 1958-02-03
US3018221A (en) * 1958-03-28 1962-01-23 Frosst & Co Charles E Penicillin-sulfonamide tablet
US2957804A (en) * 1958-06-06 1960-10-25 Harlan R Shuyler Pesticide

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4609542A (en) * 1978-12-22 1986-09-02 Elan Corporation, P.L.C. New pharmaceutical forms for administration of medicaments by oral route, with programmed release
US4726951A (en) * 1978-12-22 1988-02-23 Elan Corporation P.L.C. New pharmaceutical forms for administration of medicaments by oral route, with programmed release
GB2178658A (en) * 1985-07-26 1987-02-18 Vincent Processes Limited Sustained release tablets and a method of manufacture thereof

Also Published As

Publication number Publication date
US3102845A (en) 1963-09-03
DE1195012B (en) 1965-06-16

Similar Documents

Publication Publication Date Title
US3344029A (en) Sustained release composition
GB934089A (en) Improvements in or relating to sustained release medicaments
ES403435A1 (en) Slow release pharmaceutical compositions
US3867521A (en) Method for absorption of drugs
IL117356A (en) Controlled release matrix and pharmaceutical compositions for oral administration containing it
SE8303531D0 (en) PHARMACEUTICAL COMPOSITION
ES8402155A1 (en) Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
KR890001526A (en) Oral sustained release acetaminophen formulations and preparation method thereof
ES321779A1 (en) A method for developing pharmaceutical compositions. (Machine-translation by Google Translate, not legally binding)
AR241512A1 (en) Use of gamma-hydroxybutyric acid salts for preparing pharmaceutical compositions for use in the treatment of alcoholism, and the compositions obtained
GB1381872A (en) Pharmaceutical compositions for inhalation
MY104010A (en) Pharmaceutical compositions.
GB1171691A (en) Lond-Acting Oral Carrier
ES461399A1 (en) Epinine esters and pharmaceutical compositions thereof
DE3367324D1 (en) Pharmaceutical products in sustained-release form, and their preparation process
GB1279214A (en) Long-acting oral carrier
GB1022171A (en) Prolonged release oral pharmaceutical tablets and their manufacture
US3891755A (en) Dosage formulation for erythromycin cetyl sulfate
GB1443923A (en) Sustained release compositions
GB630439A (en) Improvements in or relating to pharmaceutical preparations
GB1302266A (en)
GB862376A (en) Sustained release pharmaceutical tablet
ES436179A1 (en) Physiological substances for intensifying the pharmacological effect of drugs
IT9020943A1 (en) PHARMACEUTICAL COMPOSITION FOR ORAL USE WITH MODIFIED RELEASE OF NON-STEROID ANTI-INFLAMMATORS
GB993601A (en) Antiviral compositions comprising adenine derivatives